Noninterventional Epigenomic Mapping of CD34+ Cells From Healthy Participants and Patients With Myelofibrosis (MF) and Polycythemia Vera (PV) (CTMS# 17-0149)
Ruben Mesa M.D.
For more information about this studyView Details
About This Study
This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or second line of therapy in patients with metastatic hormone receptor positive and HER2-positive breast cancer.